Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis
Conclusions Improvements in patient-reported physical and psychological functioning and general health status with daclizumab compared with intramuscular interferon beta-1a are consistent with outcomes on clinical and brain MRI lesion measures in DECIDE (NCT01064401).
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
More News: Avonex | Brain | Disability | MRI Scan | Multiple Sclerosis | Neurology | Psychology | Rebif | Study